Premium
Clinical pharmacokinetics of etintidine
Author(s) -
Huang ShiewMei,
Weintraub Howard S.,
Abels Robert,
Harris William,
Marriott Thomas B.,
Arnold John D.,
Boccagno Joseph
Publication year - 1988
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bod.2510090506
Subject(s) - pharmacokinetics , urine , chemistry , oral administration , creatinine , plasma concentration , endocrinology , renal function , medicine , pharmacology
The pharmacokinetics of etintidine (E), a potent H 2 blocker, were studied in 12 normal, fasted subjects. The subjects received five ascending doses of E HCI in capsules at 72‐h intervals. Blood and urine samples were collected and the plasma and urine levels of E were determined by HPLC. Following oral administration, plasma E levels showed double peaks in half of the subjects. Mean C max ., (0.42, 2.11, 3.82, 4.50, and 7.15 μg ml −1 ), AUC 0‐∞ (0.96, 4.94, 11.3, 17.5, and 24.5 h μg ml −1 ), and the amount of E excreted unchanged in 72 h (20, 54.8, 170, 320, and 371 mg) were determined. These parameters indicate the amount of E absorbed increased linearly with dose for each individual. Renal clearance was independent of the dose and the mean value (16.6 lh −1 ) was about twice that of the creatinine clearance (which did not significantly change as a result of E treatment), indicating that E is actively secreted into the renal tubules. As E was eliminated rapidly from the body (t ½ <2 h), no substantial accumulation of E is expected after multiple dose treatment.